Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented one oral presentation and three posters related to seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress that took place January 29th through February 1st in Rio de Janeiro, Brazil.Posters Related to Seralutinib, an Inhaled PDGFR, CSF1R and c-KIT Inhibitor:Preclinical Models Support the Synergistic Potential of Seralutinib and Sotatercept in Treating Pulmonary Arterial HypertensionLink: https://goss.bio/4h0uBJiSustained Benefit with Seralutinib Treatment: A Post-Hoc Analysis of the TORREY Open-Label ExtensionLink: https://goss.bio/3CmVuYuSustained Effect of Seralutinib on Circulating Biomarkers in the TORREY Phase 2 Open-Label Extension S
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Gossamer Bio: High-Risk Binary Approaches [Seeking Alpha]Seeking Alpha
- Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- How Recent Developments Are Shaping the Gossamer Bio Investment Story [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio to Participate in Upcoming Investor ConferencesBusiness Wire
- Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
GOSS
Earnings
- 11/5/25 - Miss
GOSS
Sec Filings
- 11/5/25 - Form 8-K
- 11/5/25 - Form 10-Q
- 10/2/25 - Form 4
- GOSS's page on the SEC website